QingSong Health Corp (2661.HK) Stock Competitors & Peer Comparison

2661.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2661.HK stands at 1.3B. In comparison, 0241.HK has a market cap of 56.5B. Regarding current trading prices, 2661.HK is priced at HK$6.50, while 0241.HK trades at HK$3.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2661.HK currently has a P/E ratio of -1.22, whereas 0241.HK's P/E ratio is 26.29. In terms of profitability, 2661.HK's ROE is N/A, compared to 0241.HK's ROE of +0.11%. Regarding short-term risk, 2661.HK is more volatile compared to 0241.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2661.HK.Check 0241.HK's competition here

2661.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2661.HK stands at 1.3B. In comparison, 2228.HK has a market cap of 30.3B. Regarding current trading prices, 2661.HK is priced at HK$6.50, while 2228.HK trades at HK$7.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2661.HK currently has a P/E ratio of -1.22, whereas 2228.HK's P/E ratio is -99.37. In terms of profitability, 2661.HK's ROE is N/A, compared to 2228.HK's ROE of +0.02%. Regarding short-term risk, 2661.HK is more volatile compared to 2228.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2661.HK.Check 2228.HK's competition here

2661.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2661.HK stands at 1.3B. In comparison, 1833.HK has a market cap of 16.3B. Regarding current trading prices, 2661.HK is priced at HK$6.50, while 1833.HK trades at HK$7.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2661.HK currently has a P/E ratio of -1.22, whereas 1833.HK's P/E ratio is 28.86. In terms of profitability, 2661.HK's ROE is N/A, compared to 1833.HK's ROE of +0.04%. Regarding short-term risk, 2661.HK is more volatile compared to 1833.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2661.HK.Check 1833.HK's competition here

2661.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2661.HK stands at 1.3B. In comparison, 2506.HK has a market cap of 5.5B. Regarding current trading prices, 2661.HK is priced at HK$6.50, while 2506.HK trades at HK$70.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2661.HK currently has a P/E ratio of -1.22, whereas 2506.HK's P/E ratio is -112.22. In terms of profitability, 2661.HK's ROE is N/A, compared to 2506.HK's ROE of N/A. Regarding short-term risk, 2661.HK is more volatile compared to 2506.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2661.HK.Check 2506.HK's competition here

2661.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2661.HK stands at 1.3B. In comparison, 2158.HK has a market cap of 5B. Regarding current trading prices, 2661.HK is priced at HK$6.50, while 2158.HK trades at HK$4.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2661.HK currently has a P/E ratio of -1.22, whereas 2158.HK's P/E ratio is 61.51. In terms of profitability, 2661.HK's ROE is N/A, compared to 2158.HK's ROE of +0.02%. Regarding short-term risk, 2661.HK is more volatile compared to 2158.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2661.HK.Check 2158.HK's competition here

2661.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2661.HK stands at 1.3B. In comparison, 2361.HK has a market cap of 2.1B. Regarding current trading prices, 2661.HK is priced at HK$6.50, while 2361.HK trades at HK$5.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2661.HK currently has a P/E ratio of -1.22, whereas 2361.HK's P/E ratio is 21.38. In terms of profitability, 2661.HK's ROE is N/A, compared to 2361.HK's ROE of N/A. Regarding short-term risk, 2661.HK is more volatile compared to 2361.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2661.HK.Check 2361.HK's competition here

2661.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2661.HK stands at 1.3B. In comparison, 2587.HK has a market cap of 1.9B. Regarding current trading prices, 2661.HK is priced at HK$6.50, while 2587.HK trades at HK$2.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2661.HK currently has a P/E ratio of -1.22, whereas 2587.HK's P/E ratio is 30.86. In terms of profitability, 2661.HK's ROE is N/A, compared to 2587.HK's ROE of N/A. Regarding short-term risk, 2661.HK is more volatile compared to 2587.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2661.HK.Check 2587.HK's competition here

2661.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2661.HK stands at 1.3B. In comparison, 6819.HK has a market cap of 1.8B. Regarding current trading prices, 2661.HK is priced at HK$6.50, while 6819.HK trades at HK$4.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2661.HK currently has a P/E ratio of -1.22, whereas 6819.HK's P/E ratio is -22.56. In terms of profitability, 2661.HK's ROE is N/A, compared to 6819.HK's ROE of -6.90%. Regarding short-term risk, 2661.HK is more volatile compared to 6819.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2661.HK.Check 6819.HK's competition here

2661.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2661.HK stands at 1.3B. In comparison, 2389.HK has a market cap of 478.6M. Regarding current trading prices, 2661.HK is priced at HK$6.50, while 2389.HK trades at HK$0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2661.HK currently has a P/E ratio of -1.22, whereas 2389.HK's P/E ratio is -4.12. In terms of profitability, 2661.HK's ROE is N/A, compared to 2389.HK's ROE of -0.06%. Regarding short-term risk, 2661.HK is more volatile compared to 2389.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2661.HK.Check 2389.HK's competition here

2661.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2661.HK stands at 1.3B. In comparison, 2159.HK has a market cap of 437M. Regarding current trading prices, 2661.HK is priced at HK$6.50, while 2159.HK trades at HK$1.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2661.HK currently has a P/E ratio of -1.22, whereas 2159.HK's P/E ratio is -6.57. In terms of profitability, 2661.HK's ROE is N/A, compared to 2159.HK's ROE of +0.11%. Regarding short-term risk, 2661.HK is more volatile compared to 2159.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2661.HK.Check 2159.HK's competition here

2661.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2661.HK stands at 1.3B. In comparison, 2415.HK has a market cap of 361.4M. Regarding current trading prices, 2661.HK is priced at HK$6.50, while 2415.HK trades at HK$0.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2661.HK currently has a P/E ratio of -1.22, whereas 2415.HK's P/E ratio is 22.00. In terms of profitability, 2661.HK's ROE is N/A, compared to 2415.HK's ROE of N/A. Regarding short-term risk, 2661.HK is less volatile compared to 2415.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2661.HK.Check 2415.HK's competition here